In this episode of the Exploring Artificial Intelligence (AI) in Oncology series, Waqas Haque, MD, MPH, Hematology/Oncology Fellow at the University of Chicago, speaks with Osama Khan, MD, Staff Pathologist at Natera, a cell-free DNA (cfDNA) technology company that aims to make personalized genetic testing and diagnostics part of the standard of care. Dr. Khan shares insights into how digital pathology and emerging technologies like AI and measurable residual disease (MRD) testing are revolutionizing oncology, driving precision medicine, and enhancing patient care.

Learn more at: https://oncdata.com/digital-pathology-osama-khan 

From Glass Slides to AI: How Digital Pathology and MRD Testing Are Transforming Cancer Care With Osama Khan, MD, and Waqas Haque, MD, MPH

The mission of Oncology Data Advisor is to provide the multidisciplinary team with expert insights into clinical best practices and research progress in cancer care.

From Glass Slides to AI: How Digital Pathology and MRD Testing Are Transforming Cancer Care With Osama Khan, MD, and Waqas Haque, MD, MPH

Oncology Data Advisor®